Nordic Capital and Astorg have announced an agreement to jointly acquire Cytel, from New Mountain Capital
Cytel is one of the largest providers of statistical software and advanced analytics for clinical trial design and biometrics execution. Building on Cytel’s advanced software platform and leading biometrics services offerings, the new owners will invest in the business’s continued development and software.
“We are delighted to welcome Nordic Capital and Astorg as our new owners and partners. They have an extensive track-record of commitment to medicine and data science, and we share several common experiences in developing and growing leading healthcare and technology businesses. This common foundation of vision and values makes them ideal to support our continued growth and strategy. With Nordic Capital and Astorg, we have strong new partners at our side with expertise networks, cultural fit and a focus on innovation and quality that will benefit both our customers and employees,” said Joshua Schultz, CEO, Cytel.
“We are proud of Cytel’s leading position and growth in enabling clinical trial optimisation for the advancement of life-saving therapeutics. Over the past three years, New Mountain supported the transformation of Cytel into a cutting-edge pharma technology and analytics platform through strategic acquisitions and organic business building,” said Kyle Peterson, managing director, New Mountain Capital.
